MME and cancer: Albrecht et al. [19] have reported a shift from membrane bound to cytoplasmic localization for CD10 in high-grade prostate cancer cells with a loss of CD10 expression in areas of high proliferative activity as indicated by Ki67 immunohistochemistry (n = 24, with perhaps around 7 containing CD10+ cancer cells based on their frequency).